The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...

The cancer vaccine market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising number of cancer diagnoses, heightened awareness of cancer vaccines, ...

CT imaging of patients entering lung cancer treatment identified a high prevalence of atherosclerosis, according to data ...

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed ...